ABION Inc. is a Korea-based company principally engaged in the research, development and sales of pharmaceuticals. Along with its subsidiaries, the Company operates its business through four segments including product segment, contract research organization (CRO) service segment, research segment and other segment. The Product segment produces and sells diagnostic reagents, research reagents, and stem cell culture medium. The CRO Service segment provides histopathology analysis, molecular genetic analysis, cellular immunoassay, and antibody detection services. The Research segment is engaged in research and development of drugs for protein therapeutics, nucleic acid therapeutics, and antibody therapeutics.

Employees

Sector

Biotechnology & Medical Research

Calendar

10-08 Significant Split/Dividend

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 14/08/2026			5-day change	1st Jan Change
676.00 ^KRW	-2.03%		-.--%	-78.40%

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE

Market Cap	60.91B 45.23M 40.18M 37.5M 34.18M 64.47M 4.35B 65.07M 454M 176M 2.22B 170M 166M 7.13B	P/E 2024	-4.02x	P/E 2025	-7.21x
Enterprise Value	32.57B 24.19M 21.49M 20.06M 18.28M 34.48M 2.33B 34.8M 243M 94.06M 1.19B 90.81M 88.84M 3.81B	EV / Sales 2024	282x	EV / Sales 2025	288x
Free-Float	73.67%	Yield 2024 *	-	Yield 2025	-

04-07	ABION Announces Preclinical Data Showing IFN-? Antibody Fusion Abn202 Outperforms Trop2-Targeting ADCs	CI
04/04/25	Abion To Divest 5.9 Billion Won Worth Of Shares In Vivozon Inc	RE
30/12/24	Nuon Co., Ltd. completed the acquisition of 4.06% stake in ABION Inc. from KPM TECH Co., Ltd..	CI
26/12/24	KPM TECH Co., Ltd. announced that it has received KRW 5.999999711 billion in funding from ABION Inc.	CI
23/12/24	Nuon Co., Ltd. agreed to acquire 4.06% stake in ABION Inc. from KPM TECH Co., Ltd. for KRW 8 billion.	CI
23/12/24	ABION Inc. announced that it has received KRW 8.0011152 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
18/12/24	KPM TECH Co., Ltd. announced that it expects to receive KRW 5.999999711 billion in funding from ABION Inc.	CI
05/12/24	ABION Inc. completed the acquisition of 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc..	CI
05/12/24	ABION Inc. announced that it has received KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. announced that it expects to receive KRW 20.019993378 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
11/11/24	ABION Inc. agreed to acquire 7.56% stake in Vivozon, Inc. from TELCON RF PHARMACEUTICAL. Inc. for KRW 20.1 billion.	CI
28/10/24	ABION Inc. announced that it expects to receive KRW 9.999995616 billion in funding from TELCON RF PHARMACEUTICAL. Inc.	CI
28/12/23	Abion Inc. announced that it has received KRW 7.999997049 billion in funding from TELCON RF PHARMACEUTICAL. Inc., Gencurix Inc.	CI

1 day	-2.03%
3 months	-14.86%
6 months	-70.48%
Current year	-78.40%

Abion Inc. Stock

Stocks

A203400

KR7203400007

Biotechnology & Medical Research

Valuation: Abion Inc.

Chart: Abion Inc.

Latest news: Abion Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Abion Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Current year	570	4,335
1 year	570	4,510
3 years	570	7,277.78
5 years	570	9,777.78
10 years	570	14,694.44

Manager	Title	Age	Since
Young-Gi Shin CEO	Chief Executive Officer	55	01/08/2010
Seong-Yun Woo DFI	Director of Finance/CFO	45	28/03/2025
Gi-Ryong Jang COO	Chief Operating Officer	46	01/01/2026

Director	Title	Age	Since
Young-Gi Shin BRD	Director/Board Member	55	31/12/2014
Jin-Wook Yang BRD	Director/Board Member	56	25/03/2022
Geun-Chul Park BRD	Director/Board Member	70	-

Date	Insider	Type	Quantity	% Market Cap.	Importance
8/12/25	Sun-mi Chang	Free	27	0.0001%	-
8/12/25	Yang-mi Lim	Buy	115	0.0002%
8/12/25	Yang-mi Lim	Free	92	0.0002%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABION INC.	-2.03%	-.--%	-76.33%	-82.64%	45.23M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.41%	-2.49%	+41.32%	+99.99%	39.06B
Weighted average by Cap.	+0.12%	-0.84%	+58.75%	+129.88%

	2024	2025
Net sales	760M 564K 501K 468K 426K 804K 54.23M 812K 5.66M 2.19M 27.72M 2.12M 2.07M 88.97M	880M 654K 581K 542K 494K 932K 62.82M 940K 6.56M 2.54M 32.12M 2.45M 2.4M 103M
Net income	-43.38B -32.21M -28.62M -26.71M -24.35M -45.92M -3.1B -46.35M -323M -125M -1.58B -121M -118M -5.08B	-29.06B -21.58M -19.17M -17.9M -16.31M -30.76M -2.07B -31.05M -217M -83.92M -1.06B -81.02M -79.26M -3.4B
Net Debt	14.05B 10.43M 9.27M 8.65M 7.88M 14.87M 1B 15.01M 105M 40.56M 513M 39.16M 38.31M 1.65B	-28.33B -21.04M -18.69M -17.45M -15.9M -29.99M -2.02B -30.27M -211M -81.81M -1.03B -78.99M -77.27M -3.32B